• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Kezar to commence Phase IIa autoimmune hepatitis therapy trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 04, 2022 at 10:52: AM
via Kezar Life Sciences has announced plans to commence the Phase IIa PORTOLA clinical trial (KZR-616-208) of zetomipzomib to treat autoimmune hepatitis.

The move comes after the US Food and Drug Administration granted clearance for the Investigational New Drug (IND) application of Kezar Life Sciences for zetomipzomib.

article source
 

<



Similar threads

cafead
Kezar stalls solid tumor trial to focus on autoimmune disease candidate
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Amgen spinout Kezar hits PhII hurdle, all eyes on June readout for drug’s other study
Replies
0
Views
194
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Satellos to commence Phase I trial for DMD drug
Replies
0
Views
11
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Genfit moves to jump-start enrollment in slow-going phase 2 liver failure trial
Replies
0
Views
3
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote